Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss in SLE patients is mostly due to chronic telogen effluvium and is linked to moderate disease activity.

Skin problems are common in lupus patients and should be treated early to prevent worsening.

Certain KIR genes in Indian SLE patients are linked to disease severity and could be biomarkers.

Genetic screening for NUDT15 polymorphisms is crucial for patients taking azathioprine, especially in Asians.

A woman with lupus had blood cell destruction, treated successfully with medication.

About 8% of people with systemic lupus erythematosus have chronic scarring alopecia, with certain symptoms and positive antibodies increasing the risk, while immunosuppressants may lower it.

Autoimmune diseases can cause hair loss, and early treatment is important to prevent permanent damage.

Systemic lupus erythematosus is diagnosed earlier in males than females.

Alopecia is common in lupus patients, causing significant anxiety and is linked to the disease itself.

COVID-19 vaccines had more side effects and worse perception than flu vaccines in Korean lupus patients.

A TNFAIP3 gene mutation can cause unusual and varied symptoms of lupus and Sjogren's syndrome.

Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.

Older men with late-onset lupus have a higher mortality rate than women.

The Polish Dermatological Society recommends personalized treatment for cutaneous lupus, including lifestyle changes, medications, and monitoring, with specific drugs for severe cases.

Early treatment of Lupus Erythematosus Alopecia can prevent permanent hair loss, and various medications are effective.

Recognizing LET and AITD can help diagnose SLE early for better treatment.

Macrophage activation syndrome can be a deadly first sign of systemic lupus erythematosus.

The session covered updates on skin treatments, including radiotherapy, imiquimod, acitretin, JAK inhibitors, and strategies for managing rosacea and preventing surgical infections.

Higher EULAR/ACR scores in SLE patients predict more organ damage.

The 2012 criteria are better for diagnosing atypical lupus cases.

The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.

Higher disease activity in systemic lupus erythematosus is strongly linked to more internal organ damage.

New tools and criteria have been developed to better assess and treat pediatric lupus.

Lupus treatment requires a combination of drugs and therapies, with research needed for new options.

Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.

Tjalma Syndrome is a rare condition in people with lupus, causing fluid buildup and high CA-125 levels, but not due to tumors.

Excluding alopecia and mucous membrane components from the CLASI-A score reduces its effectiveness in capturing important disease activity.

The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.

Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.